Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. by Haddad, RI et al.
UC San Diego
UC San Diego Previously Published Works
Title
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: 
role, controversy, and future directions.
Permalink
https://escholarship.org/uc/item/6bp7g2jf
Journal
Annals of oncology : official journal of the European Society for Medical Oncology, 29(5)
ISSN
0923-7534
Authors
Haddad, RI
Posner, M
Hitt, R
et al.
Publication Date
2018-05-01
DOI
10.1093/annonc/mdy102
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
REVIEW
Induction chemotherapy in locally advanced
squamous cell carcinoma of the head and neck:
role, controversy, and future directions
R. I. Haddad1, M. Posner2, R. Hitt3, E. E. W. Cohen4, J. Schulten5, J.-L. Lefebvre6 & J. B. Vermorken7*
1Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston; 2The Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn
School of Medicine at Mount Sinai, New York City, USA; 3Department of Medical Oncology, University Hospital Severo Ochoa, Madrid, Spain; 4Department of
Medicine, University of California, San Diego, La Jolla, USA; 5Merck KGaA, Darmstadt, Germany; 6Head and Neck Department, Centre Oscar Lambret, Lille, France;
7Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
*Correspondence to: Dr Jan B. Vermorken, Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium. Tel: þ32-3-8214548;
E-mail: janb.vermorken@uza.be
Background: The value of induction chemotherapy (ICT) remains under investigation despite decades of research. New
advancements in the field, specifically regarding the induction regimen of choice, have reignited interest in this approach for
patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Sufficient evidence has
accumulated regarding the benefits and superiority of TPF (docetaxel, cisplatin, and fluorouracil) over the chemotherapy
doublet cisplatin and fluorouracil. We therefore sought to collate and interpret the available data and further discuss the
considerations for delivering ICT safely and optimally selecting suitable post-ICT regimens.
Design: We nonsystematically reviewed published phase III clinical trials on TPF ICT in a variety of LA SCCHN patient
populations conducted between 1990 and 2017.
Results: TPF may confer survival and organ preservation benefits in a subgroup of patients with functionally inoperable or
poor-prognosis LA SCCHN. Additionally, patients with operable disease or good prognosis (who are not candidates for organ
preservation) may benefit from TPF induction in terms of reducing local and distant failure rates and facilitating treatment
deintensification in selected populations. The safe administration of TPF requires treatment by a multidisciplinary team at an
experienced institution. The management of adverse events associated with TPF and post-ICT radiotherapy-based treatment is
crucial. Finally, post-ICT chemotherapy alternatives to cisplatin concurrent with radiotherapy (i.e. cetuximab or carboplatin plus
radiotherapy) appear promising and must be investigated further.
Conclusions: TPF is an evidence-based ICT regimen of choice in LA SCCHN and confers benefits in suitable patients when it is
administered safely by an experienced multidisciplinary team and paired with the optimal post-ICT regimen, for which,
however, no consensus currently exists.
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Introduction
The role of induction chemotherapy (ICT) in locally advanced
squamous cell carcinoma of the head and neck (LA SCCHN) has
been heavily investigated, yet clear guidelines for the optimal use
of ICT outside of cases where organ preservation is a primary
goal have yet to be defined. Available data have been primarily in-
conclusive regarding whether ICT confers overall superior bene-
fits versus the standard of care (concurrent chemoradiotherapy),
except in the larynx preservation setting [1–3], because a defini-
tive phase III trial has yet to be completed in other settings.
Moreover, it has taken >2 decades to arrive at a consensus,
evidence-based ICT regimen of choice: TPF [docetaxel, cisplatin,
and fluorouracil (5-FU)]. TPF is now accepted to be superior to
PF (cisplatin plus 5-FU) in multiple phase III trials and a meta-
analysis (Table 1 and supplementary Table S1, available at Annals
of Oncology online) [4–10].
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Table 1. Summary of phase III trials involving ICT in LA SCCHN between 1990 and 2017
Study # Patients Regimen Resectability
Criteria
Primary End Point:
Outcome
Toxicity
Spain 1998 [7] 382 PF! cisplatin-RT/surgery
versus TPF! cisplatin-RT/
surgery
Stages III–IV resectable
and unresectable
disease
Complete response
rate: higher in TPF
arm
Patients in the PF arm had sig-
nificantly more grades 2–4
mucositis than patients in
TPF arm
TAX 324 [5] 501 PF! carboplatin-RT versus
TPF! carboplatin-RT
Unresectable or re-
sectable (suitable
for organ
preservation)
OS: higher OS in TPF
arm
Rates of neutropenia and febrile
neutropenia were higher in the
TPF arm
CT was more frequently delayed
due to AEs in the PF arm
TAX 323/EORTC
24971 [4]
358 PF! RT versus TPF! RT Unresectable disease PFS: higher PFS and
OS in TPF arm
More grade 3/4 leukopenia and
neutropenia in the TPF arm
More grade 3/4 thrombocyto-
penia, nausea, vomiting, stoma-
titis, and hearing loss in the PF
arm
Rates of death from toxicity: 2.3%
versus 5.5% in TPF versus PF
arms
TTCC 2002 [8] 439 PF! cisplatin-RT versus
TPF! cisplatin-RT versus
cisplatin-RT
Unresectable disease PFS and TTF: no differ-
ence in either
Toxicity in ICT arms was
manageable
GORTEC 2000-01
[9, 10]
213 PF! RT/surgery versus
TPF! RT/surgery
Disease suitable for
total laryngectomy
Larynx preservation:
higher 3-, 5-, and
10-year larynx pres-
ervation rates (and
ORR) in TPF arm
Patients in TPF group had more
grade 4 (febrile) neutropenia
Patients in PF group had more
grade 3/4 stomatitis, thrombo-
cytopenia, and creatinine
elevation
DeCIDE [28] 285 TPF! chemo-RTa versus
chemo-RT
N2 or N3 disease OS: no difference Serious AEs were significantly
more common in the ICT
arm
PARADIGM [29] 145 TPF! chemo-RTb versus
cisplatin-RT
Unresectable disease OS: no difference Febrile neutropenia was nu-
merically more common in
the ICT! chemo-RT arm
than in the chemo-RT arm
RTOG 91-11 [49, 76] 517-520 PF! RT/surgery þ RT versus
cisplatin-RT versus RT
Glottic/supraglottic
stages III–IV LA SCC
LFS: similar efficacy
between PF! RT
and cisplatin-RT
Higher rate of non–treatment-/
disease-related death
occurred with cisplatin-RT
versus PF! RT and RT alone
EORTC 24954 [48] 450 A: PF! RT/surgery versus B:
(PF! RT) 3! PF
Resectable laryngeal/
hypopharyngeal
disease
Larynx preservation:
OS with functional
larynx was numeric-
ally improved in
arm B versus A
Grade 3/4 mucositis was nu-
merically lower in arm B ver-
sus A
Italian trial [27] 414 TPF! cisplatin-RT or cetuxi-
mab-RT versus cisplatin-RT
or cetuximab-RT
Stages III–IV disease of
the oral cavity, oro-
pharynx,
hypopharynx
OS: Higher with TPF
than without
LRC: Higher with TPF
than without
Induction TPF did not affect
compliance to cetuximab-RT
and cisplatin-RT
aDocetaxel, 5-FU, hydroxyurea.
bDocetaxel or carboplatin.
5-FU, fluorouracil; AE, adverse event; CT, chemotherapy; EORTC, European Organisation for Research and Treatment of Cancer; ICT, induction chemother-
apy; LA SCCHN, locally advanced squamous cell carcinoma of the head and neck; LFS, laryngectomy-free survival; LRC, locoregional control; ORR, overall re-
sponse rate; OS, overall survival; PF, cisplatin plus 5-FU; PFS, progression-free survival; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group; TTF, time
to treatment failure; TPF, docetaxel, cisplatin, and 5-FU.
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Although radiotherapy is the only post-ICT regimen current-
ly supported by level IA evidence in the European Society for
Medical Oncology guidelines [11], a strong interest in adding a
sensitizing agent to radiotherapy post-ICT has become evident
in recently-initiated clinical trials. Accordingly, we consider
both radiotherapy with/without carboplatin post-ICT as
standard-of-care options (the former being commonly used in
the United States). We have, therefore, pooled our knowledge
and experience regarding the indications for TPF and other ICT
regimens to review and interpret the available phase III data
concerning the utility of ICT in LA SCCHN. We review the
phase III evidence, published in 1990–2017, for TPF as the new
gold-standard, evidence-based ICT regimen of choice and dis-
cuss the settings where induction TPF may confer benefits in
patients with LA SCCHN over the current standard of care. The
goal of this communication is to provide a future perspective on
its use and role for the treatment of LA SCCHN in clinical
practice.
Available treatment options in LA SCCHN
The current available treatment options for patients with LA
SCCHN are mapped out in Figure 1 [11]. For patients with oper-
able disease where organ preservation is a key therapy goal, the
available options are concurrent chemoradiotherapy or sequen-
tial treatment with induction TPF! radiotherapy (although
radiotherapy and carboplatin/cisplatin/cetuximab are being
investigated as post-ICT options as well) [12, 13]. The treatment
options available to patients with unresectable LA SCCHN in-
clude radiotherapy and cisplatin, carboplatin and 5-FU (French
regimen), or cetuximab (for cisplatin-unsuitable patients). More
controversial is the use of ICT followed by a radiotherapy or che-
moradiotherapy as a routine treatment in patients with inoper-
able disease.
TPF as a breakthrough for ICT
TPF has now been established as an ICT regimen that yields better
response rates and a milder toxicity profile than earlier induction
regimens, including PF. The superiority of TPF over PF has been
confirmed via meta-analysis of the pooled data from 5 phase III
studies (Spain 1998, TAX 323/EORTC 24971, TAX 324,
GORTEC 2000-01, and TTCC 2002, representing a total of 1772
patients; Table 1) conducted by Blanchard et al. [6], which con-
cluded that patients who receive TPF versus PF experience bene-
fits in progression-free survival (PFS), overall survival (OS), and
in locoregional failure rate (LFR) and distant failure rate (DFR)
[6]. Consistent with these findings, Blanchard et al. [6] found
that the calculated hazard ratio (HR) for death (0.79) strongly
favored the TPF regimen. Of note, however, limitations of this
meta-analysis included the use of pooling methodology on five
rather heterogeneous studies (especially regarding the selection
of and administration practices for post-ICT regimens) and a
general concern regarding partially or completely missing treat-
ment failure data for the Spain 1998, TAX 323/EORTC 24971,
and TTCC 2002 trials [14]. Finally, ICT responders and nonres-
ponders commonly received different follow-up treatments, fur-
ther complicating any meta-analysis of the benefits of sequential
chemotherapy.
Nevertheless, improved safety with the addition of docetaxel to
the PF doublet ICT regimen has been observed in clinical trials.
In the TAX 323/EORTC 24971 trial, more patients completed
treatment in the TPF arm than did patients in the PF arm (75.7%
versus 65.7%, respectively), and fewer deaths from toxicity were
encountered (2.3% versus 5.5%), and in the TAX 324 trial, fewer
patients had treatment delays in the TPF arm versus in the PF
arm (29% versus 65%, respectively) [4, 5]. Across all five studies,
patients who received TPF experienced fewer grade 3/4 mucositis
events and had lower frequencies of nausea, vomiting, stomatitis,
and hearing loss (likely owed to the reduction in dosage of
Locally advanced
(stage III–IVA, IVB)
Resectable Unresectable
(CCt)RT ICT→
(CCt)RT
Red = controversial
ICT→
(CCt)RT
Operable
Surgery
Follow-up (CCt)RT (CCt)RT
(CCt)RT = radiotherapy
(concomitant with systemic therapy)
Organ preservation strategy
(Nonsurgical approach*)
Not operable
Figure 1. Current standard-of-care paradigm in LA SCCHN. *ICT!RT is only an accepted standard approach for larynx preservation in locore-
gionally advanced larynx and hypopharynx cancer. ICT, induction chemotherapy; LA SCCHN, locally advanced squamous cell carcinoma of
the head and neck.
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cisplatin and 5-FU). Furthermore, the rate of toxicity-related
deaths tended to be lower among patients in the TPF arms, and
the only adverse events that appeared to be more prevalent with
TPF versus PF were neutropenia, febrile neutropenia, and leuko-
penia (Table 1) [4, 5, 7–10].
Further analysis of TAX 323/EORTC 24971 also demonstrated
improved quality of life (QoL) in patients in the TPF versus PF
arms, including a decrease in swallowing problems and coughing.
Measured using the European Organisation for Research and
Treatment of Cancer (EORTC) QoL Questionnaire C30, global
QoL was statistically significantly higher in the TPF versus the PF
arm following completion of radiotherapy (at 6 months after
treatment initiation); the numerical difference in global health-
related QoL scores of 9.5 points almost reached the accepted 10-
point margin for clinically meaningful change in QoL [15].
Finally, economic analyses of TAX 323/EORTC 24971 and TAX
324 showed TPF is more cost-effective than PF, with a gain of
0.33–0.41 quality-adjusted life-years in the TPF arms of the two
trials [16]. The cost–utility ratio of TPF induction was also deter-
mined to be comparable to that observed for other widely
accepted treatment options [16].
Additional studies also investigated whether another triplet
regimen, TPE (taxane, platinum, and cetuximab), can be effective
as ICT. Although no randomized phase III trials comparing
TPE versus TPF induction have been completed, the available
early results of smaller studies using TPE have been encouraging
[17–21]. For example, response rates and OS rates of >80% at
2–5 years have been reported for patients who complete a TPE
induction regimen [18–20]. Notably, however, adding a
fourth agent (such as cetuximab) to TPF has proven difficult,
necessitating either a reduction in the TPF dose or the removal
of the 5-FU component to prevent unacceptable toxicity
[17, 22, 23].
TPF regimens and what it takes to
administer them
Two key randomized phase III trials have established standard
practices for the safe administration of TPF: the European trial
TAX 323/EORTC 24971 and the American trial TAX 324. The
TAX 323/EORTC 24971 study delivered four cycles of TPF
[75 mg/m2 docetaxel, 75 mg/m2 cisplatin, both on day 1 and
750 mg/m2/day 5-FU by continuous intravenous (i.v.) infusion
for five consecutive days] followed by radiotherapy and conferred
significant survival benefits in a population of patients with pre-
viously untreated, unresectable LA SCCHN. Results indicated
that TPF! radiotherapy prolonged PFS (median, 11.0 versus
8.2 months in the TPF versus PF arms of TAX 323, respectively),
reduced risk of death by 27% (Figure 2), and prolonged OS (me-
dian, 18.8 months versus 14.5 months in the TPF versus PF arms
of TAX 323, respectively) over PF ICT [4]. Furthermore, this TPF
regimen, when applied in larynx preservation trials such as
GORTEC 2000-01, increased the rates of 3-, 5-, and 10-year lar-
ynx preservation by 12.8%, 15.9%, and 23.8%, respectively, over
PF, and significantly improved laryngeal dysfunction-free
survival [9, 10]. Similar findings were observed with the TPF regi-
men used in the TAX 324 study (three cycles of 75 mg/m2 doce-
taxel, 100 mg/m2 cisplatin, both on day 1 and 1000 mg/m2/day
5-FU by continuous i.v. infusion for four consecutive days), with
carboplatin (area under the curve of 1.5) plus radiotherapy as the
post-ICT therapy, where median OS more than doubled in the
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Figure 2. TPF versus PF in two different patient cohorts (TAX 323/EORC 24971 and TAX 324). 5-FU, fluorouracil; HR, hazard ratio; mOS, me-
dian overall survival; PF, cisplatin plus 5-FU; RT, radiotherapy; TPF, docetaxel, cisplatin, and 5-FU. From Refs [4, 5]. Copyright VC 2007
Massachusetts Medical Society. Reprinted with permission.
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TPF arm versus the PF arm (71 versus 30 months, respectively).
Notably, the patient population of TAX 324 included patients
with LA SCCHN that was either unresectable or of low surgical
curability, as well as patients with LA SCCHN who were candi-
dates for organ preservation strategy [5]. Both trials concluded
that the overall response rate (ORR) with TPF was significantly
(TAX 323/EORTC 24971) or numerically (TAX 324) higher than
with PF [4, 5]. Both the TAX 323/EORTC 24971 and TAX 324
TPF regimens demonstrated clear survival benefits over PF ICT
in patients with unresectable LA SCCHN. Although previous
studies have demonstrated benefit with ICT! radiotherapy ver-
sus radiotherapy alone in unresectable disease [24, 25], the role of
ICT versus concurrent chemoradiotherapy in unresectable/inop-
erable disease remains controversial, due to difficulties in trial
design, execution or insufficient patient accrual [26–29].
However, in most of these studies, the sequential design
induced more toxicity than the concurrent design. A recent re-
port of GORTEC 2007-02, comparing TPF followed by cetuxi-
mab/radiotherapy versus concurrent chemoradiation with
carboplatin/5-FU in patients with inoperable LA SCCHN showed
no improvement in PFS, OS or LRC, but a significant delay in
distant metastases in the TPF arm, with more toxicity and 7%
TPF-related deaths [30, 31].
Notably, the TAX 323/EORTC 24971 regimen was associated
with a more favorable safety profile than the previously standard
PF regimen, likely owing to the lower overall doses of cisplatin
(75 mg/m2 instead of 100 mg/m2 on day 1) and 5-FU (750 mg/
m2/day 5 instead of 1000 mg/m2/day 4) (Table 2).
Consequently, patients in TAX 323/EORTC 24971 received four
cycles of ICT versus three cycles in TAX 324, while experiencing a
lower frequency of grade 3/4 stomatitis, nausea/vomiting, dys-
phagia, and neutropenia [4, 5]. Accordingly, we suggest that the
less dose-dense TPF regimen administered in TAX 323/EORTC
24971 may come with milder toxicities than the regimen used in
TAX 324 [4, 5], but both regimens are suitable for ICT and sub-
ject to the institution’s preference. Crucially, however, any TPF
regimen should be administered by experienced oncologists fa-
miliar with the necessary protocols and supportive care require-
ments to ensure patient safety and maximize adherence
throughout the treatment. Investigators of the GSTTC Italian
Collaborative Group study [27] showed that a modified dose of
TPF (docetaxel 75 mg/m2, cisplatin 80 mg/m2, and 5-FU 800 mg/
m2/day 96 hours) given in three cycles did not compromise
subsequent chemoradiotherapy in a phase II study, although no
randomized phase III trials have been completed to compare TPF
versus modified TPF. Additionally, adaptation of ICT doses may
be needed regionally, particularly in Asia, to maximize patient
safety [32].
Sequential chemotherapy poses unique challenges, partially
due to the lack of completed phase III trials comparing potential
post-ICT therapy options. The PARADIGM trial closed prema-
turely [27] and no definitive conclusions could be drawn from
the results (Table 1). Furthermore, due to decreased adherence in
patients receiving cisplatin during TPF and during subsequent
chemoradiotherapy (e.g. in the DeCIDE trial [28]), TPF!
cisplatin/radiotherapy may be suitable only for highly selected
patients with good to excellent performance status and no contra-
indications to cisplatin or for those who received a protocol-
driven reduced total dose of cisplatin during induction [3, 33, 34].
Alternative post-ICT therapy options, which may result in
improved patient adherence (versus cisplatin 100 mg/m2 q3w), in-
clude radiotherapy alone or radiotherapy/cetuximab or radiother-
apy/carboplatin. However, in that setting, neither radiotherapy
plus carboplatin nor radiotherapy plus cetuximab have been com-
pared with radiotherapy plus cisplatin (q3w or qw) in a phase III
trial, and no definitive conclusions can be drawn from the
TREMPLIN phase II study, partly due to the high rate of patient
dropout before radiotherapy [12, 35].
Table 2. Comparison of the TPF regimens and associated toxicities used in TAX 323/EORTC 24971 and TAX 324 (European versus American TPF regimens)
Study TPF Regimen Detailed Toxicities
TAX 323/EORTC 24971 [4]
(four cycles of TPF)
Docetaxel (75mg/m2) as a 1-h infusion on day 1 • 75.7% completed both TPF and RT per protocol
• 24% had a treatment delay during ICT
• Common (5%) grades 3–4 adverse events included: neutropenia
(76.9%), leukopenia (41.6%), alopecia (11.6%), anemia (9.2%), infection
(6.9%), febrile neutropenia (5.2%), thrombocytopenia (5.2%)
• 6.2% of patients discontinued treatment due to adverse event
• 2.3% deaths due to toxic effect of study regimen
Cisplatin (75mg/m2) as a 1-h infusion on day 1
5-FU (750mg/m2/day) by continuous infusion
on days 1–5
TAX 324 [5]
(three cycles TPF)
Docetaxel (75mg/m2) as a 1-h intravenous
infusion
• 73% completed TPF followed by carboplatin-RT per protocol
• 29% had a treatment delay during ICT
• Common ( 5%) grades 3–4 adverse events included: neutropenia
(83%), stomatitis/mucositis (21%), nausea (14%), dysphagia (13%), an-
emia/febrile neutropenia/neutropenic infection/anorexia (each 12%),
vomiting (8%), diarrhea (7%), infection (6%), and lethargy (5%)
• 6% of patients discontinued treatment due to adverse event related
to treatment
• <1% deaths due to toxic effect of study regimen
Intravenous cisplatin (100mg/m2) over a
period of 0.5–3 h
5-FU (1000mg/m2/day) as a continuous 24-h
infusion for 4 days
5-FU, fluorouracil; ICT, induction chemotherapy; RT, radiotherapy; TPF, docetaxel, cisplatin, and 5-FU.
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Additionally, discussion of the best practices for prophylaxis
and management of severe hematologic toxicity during ICT and
mucositis during radiotherapy is ongoing. Oral dexamethasone
during induction may prevent docetaxel-related hypersensitivity/
toxicity (fluid retention, skin toxicity) [4, 5]. Indeed, fluid man-
agement through i.v. means (especially on days 1–2 during TPF
administration) is crucial in preventing renal toxicity, hypovol-
emia, and severe fatigue [4, 5]. Current evidence also supports
the use of prophylactic treatment with antibiotics (e.g. cipro-
floxacin) or granulocyte colony-stimulating factor (though with
a lower amount of evidence), which may decrease incidence of
hematologic toxicities and infection associated with TPF [36, 37].
National Institute for Health and Care Excellence guidelines
specify that all patients with SCCHN be treated within the con-
text of a multidisciplinary team (MDT), considering aspects such
as patients’ psychological and nutritional state and the potential
for palliative care, addiction services, and speech therapy [38].
Furthermore, discussing patient selection within an MDT is par-
ticularly important when the planned treatment involves sequen-
tial chemotherapy because appropriate selection can prevent
subjecting patients to unsuitable treatments. Interestingly, insti-
tutional experience and familiarity with the patient population
and treatments impacts outcomes significantly. In a retrospective
analysis of the Radiation Therapy Oncology Group (RTOG) 0129
study, Wuthrick et al. [33] showed that centers with historically
low clinical trial accrual rates (calculated based on a total of 21
RTOG studies in SCCHN) tended to enroll patients with an over-
all better performance status at the start of a study and yet saw
threefold as many radiotherapy protocol deviations and a lower
5-year survival (51% versus 69%) than institutions with a histor-
ically high patient accrual rate [39]. Indeed, low-accrual centers
appeared to correlate with an HR for death 91% higher than
observed in the high-accrual centers (adjusted for prognostic
factors) [39]. It must be noted that the RTOG 0129 study was
conducted in patients with LA SCCHN but did not include an
ICT arm. However, given the additional complexities of care dur-
ing the administration of triplet chemotherapy induction, it is
likely that the experience of the institution will also correlate with
outcomes in patients receiving sequential chemotherapy.
The role of ICT in patients with high-risk
SCCHN
Patients with a high risk of distant failure (DF) and LA SCCHN
with multiple involved nodes, large-volume nodal disease, and
low nodes appear to gain certain benefits from the sequential
chemotherapy approach. In DeCIDE, patients with N2–N3 dis-
ease experienced a trend in improved recurrence-free survival
and lower cumulative incidence of SCCHN-related death with
TPF! chemoradiotherapy (versus chemoradiotherapy) [28].
Additionally, patients with N2c/N3 disease experienced an im-
provement in OS with ICT [28]. Furthermore, the location of
lymph node involvement may suggest which patients stand to
gain a longer distant metastasis-free survival, as shown in a retro-
spective study by Kim et al., who determined that patients with
present versus absent lower neck nodal involvement had a signifi-
cantly lower 5-year distant metastasis-free survival rate (34.3%
versus 55.2%, P¼ 0.008) [40]. Additionally, the same study
determined that patients with hypopharyngeal SCC may be at
higher risk of DF than those with laryngeal tumors (the risk for
patients with oropharyngeal and oral cavity disease being some-
where in the middle) [40]. A meta-analysis by Zhang et al. [41]
indicated that the ICT approach significantly reduced the DFR in
patients with unresectable disease. Yet, this was not sufficient to
yield a survival benefit.
The role of ICT in patients by operability
status
Resectability in LA SCCHN is generally determined by the extent
of disease, invasion and attainability of clear margins. Improved
outcomes with sequential chemotherapy in patients with unre-
sectable disease have been reported in several patient groups. For
example, Izawa et al. [42], based on the data from the DeCIDE
study [28], investigated whether induction TPF followed by con-
current chemoradiotherapy could contribute to a reduction in
metastases, leading to improved survival outcomes in compari-
son with platinum-based concurrent chemoradiotherapy alone
for patients with LA SCCHN with clinical stage N2c or N3 nodal
disease, or N2b disease with supraclavicular lymph node metasta-
ses. In the DeCIDE study, a trend in better survival with
TPF! chemoradiotherapy versus concurrent chemoradiother-
apy was observed for patients with N2c or N3 disease (P¼ 0.19).
Izawa et al. [42] reported that median survival in the concurrent
chemoradiotherapy arm was 14 months, while not reached in the
TPF arm at the time of publication. Although of interest, such a
retrospective analysis can have major bias. Nevertheless, we con-
sider it certainly a reason for further study of ICT in this patient
population.
An MDT can find consensus to classify tumors as resectable or
of a borderline category of resectable disease with a poor progno-
sis or poor resulting functionality (e.g. multinodal involvement
or requiring total laryngectomy) [11, 43]. This ‘functional inop-
erability’ scenario, where surgery will lead to unacceptable loss of
function, has an entire subset of guidelines for organ preserva-
tion, with the understanding that patients whose tumors have
low surgical curability could benefit from an aggressive, nonsur-
gical approach instead of initial surgery [3, 11]. Adding to the
complexity of this classification is the fact that criteria for staging
and functional inoperability differ based on primary tumor site
[44]. Kreeft et al. [43] found that certain procedures, such as total
glossectomy, are more universally recognized by surgeons as lead-
ing to unacceptable loss of function than other procedures, e.g.
total soft palate resection or resection at the base of the tongue
[43]. If there were better evidence that ICT is an efficacious sys-
temic therapeutic alternative for cases of functional inoperability,
then the decision whether to operate could be made more easily.
The recently published phase II/III study by Ghi et al. [27] sug-
gests that TPF! chemoradiotherapy or cetuximab/radiotherapy
may be effective for a mixed population of patients with low sur-
gical curability or functionally inoperable stages III–IV LA
SCCHN of the oral cavity, oropharynx and hypopharynx [27].
The chemotherapy given during the chemoradiotherapy part of
the study consisted of a relatively low cumulative dose of cisplatin
(160 mg/m2) in combination with 5-FU. Although interpretation
may be confounded by the addition of cetuximab/radiotherapy
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only in the phase III portion of the study, the reported results sug-
gested an improvement in PFS, OS, and locoregional control
(LRC) in patients receiving TPF! radiotherapy and cetuximab
or PF [27]. Due to lack of statistical power, a possible interaction
between ICT and the post-ICT regimens (cetuximab/radiother-
apy or PF/radiotherapy) could not be excluded, thereby preclud-
ing a definite answer as to what post-ICT regimen should be
preferred [45].
Larynx preservation is currently the only widely accepted setting
for patients with resectable LA SCCHN in which ICT has consen-
sus value. Patients with untreated laryngeal or hypopharyngeal LA
SCCHN and who require total laryngectomy can opt to receive (se-
quential or concurrent) chemoradiotherapy, with surgery as a sec-
ondary plan if still needed. PF ICT! radiotherapy was originally
reported to lead to a 31% complete response rate and 54% partial
response rate in a phase III trial of 332 patients with previously un-
treated laryngeal LA SCCHN [2]. At 3 years, 53% of patients were
still alive [46]. Merlano et al. [47] (and later, Lefebvre et al. [48])
used ICT (vinblastine sulfateþ bleomycinþmethotrexateþ
leucovorin and PF, respectively)! radiotherapy either sequential-
ly or on an alternating schedule [47, 48]. In Merlano et al. [47], the
alternating approach appeared to yield a better response rate and
was deemed less toxic. In Lefebvre et al. [48], survival with a func-
tional larynx was 45% and  30%–36% at 3 and 5 years, respect-
ively (Table 1) [47, 48]. However, the alternating approach is
difficult to perform in clinical practice and requires an extremely
close collaboration between the different disciplines. Nevertheless,
TPF ICT has shown even more efficacy in larynx preservation
than PF, with larynx preservation rates> 70% at 3, 5, and 10 years
[9, 10]. In the only study comparing sequential chemotherapy
(PF) and radiation with concomitant chemoradiotherapy and
radiotherapy alone (RTOG 91-11) in patients with laryngeal SCC,
the 10-year update indicated a significant improvement in
laryngectomy-free survival and a trend in improved OS with se-
quential chemotherapy over concurrent chemoradiotherapy as
well as a significantly greater number of non–treatment-related
and non–disease-related deaths in the concurrent chemoradio-
therapy arm [49]. Thus, the data appear to support ICT as the bet-
ter long-term treatment option in this patient population.
However, the ultimate conclusion on best practices for larynx
preservation will come from the phase III SALTORL trial
(NCT03340896; TPF! radiotherapy versus concurrent high-dose
cisplatin/radiotherapy for patients with T2-3, N0-2c laryngeal/
hypopharyngeal disease) currently running in France, comparing
the best available concurrent chemoradiation with the best avail-
able sequential approach.
Studies enrolling exclusively patients with operable LA
SCCHN have thus far failed to show a survival benefit with induc-
tion versus locoregional treatment [25, 50–52], suggesting that
ICT treatment may not be suitable in patients with resectable dis-
ease who are not candidates for organ preservation. Additionally,
a meta-analysis of 14 trials (n¼ 2099) also determined no signifi-
cant OS benefit from ICT versus locoregional treatment in
patients with operable disease [1]. However, three studies of
mixed populations of patients with resectable and unresectable
disease did suggest a survival benefit with PF (versus locoregional
treatment including surgery and/or radiotherapy) [24, 25] or
TPF induction (versus PF! chemoradiotherapy) [5]. The latter,
TAX 324, compared PF and TPF regimens in a mixed population
(resectable disease of low surgical curability, for organ preserva-
tion or expected poor functional outcome, partly with unresect-
able disease) and showed that TPF ICT reduced risk of death by
30% and improved loco-regional control over a PF regimen
(Figure 2) [5]. Furthermore, patients with operable disease who
received sequential therapy treatment tended to experience a
marked reduction in DFR. For example, in the phase III trial
reported by Paccagnella et al. [25] testing the role of PF ICT, the
subgroup of 66 patients with operable disease showed a 3-year
DF rate of 3% versus 31% in patients in the ICT versus no-ICT
arms [25]. Also, in the mixed population of the GETTEC trial,
comprising only oropharyngeal cancer patients, the overall risk
of DF was 36% higher in patients who did not receive ICT, al-
though this difference was not statistically significant [24]. The
effect of ICT on reducing the risk of DF is an important observa-
tion because metastatic SCCHN is usually associated with poor
prognosis and low OS (< 1 year) [53]. Therefore, the prevention
of future distant metastasis may be an important outcome to be
considered also during treatment decisions for patients with re-
sectable LA SCCHN. Although data are premature, identification
and validation of potential biomarkers for benefit from ICT will
also be crucial tools for clinicians making these treatment deci-
sions. Some such biomarkers currently under investigation in-
clude, but are not limited to, annexin A1, acetylated tubulin,
GDF15, cancer stem cell markers, p53 functional status, and low
neck nodes [30, 54–59].
Finally, it is notable that ICT may have a role in the preopera-
tive setting for cancers of the oral cavity. A meta-analysis of phase
III studies comparing ICT! surgery (with or without postopera-
tive radiotherapy) versus surgery (with or without postoperative
radiotherapy) in resectable oral cavity SCC found a potential sur-
vival benefit of ICT in patients with N2 disease [60]. A small
randomized trial identified no survival benefit of preoperative
ICT (before surgery and optional radiotherapy versus upfront
surgery and optional radiotherapy) in patients with T2–T4, N0–
N2 oral cavity SCC, but did note lowered fibrosis and dysphagia
in the ICT arm at long-term follow-up, which the investigators
ascribed to the fact that, with the use of ICT, less extensive surgery
had to be carried out and fewer patients needed to receive postop-
erative radiation [61].
The role of ICT in human
papillomavirus-associated LA SCCHN
Patients with human papillomavirus (HPV)–associated LA
SCCHN generally have more favorable prognoses, better
responses to therapy, and longer OS than do patients with HPV-
negative disease [62–65]. The prognostic value of HPV and p16
positivity has been demonstrated in the ICT (paclitaxel/carbopla-
tin or TPF) setting, where patients with HPV-positive disease had
a higher ORR and more than double the 5-year survival rates ver-
sus patients with HPV-negative disease [66, 67]. In the phase II
Eastern Cooperative Oncology Group 1308 study, Marur et al.
[68] suggested that ICT with cisplatin/paclitaxel/cetuximab may
allow patients with HPV-positive oropharyngeal carcinoma and
an otherwise favorable prognosis to undergo reduced-dose inten-
sity-modulated radiation therapy (IMRT) without reducing
efficacy. This chemoradiotherapy de-escalation plan led to a
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significant decrease in radiotherapy-associated toxicities, such as
difficulty swallowing or impaired nutrition, compared with
patients who received regular-dose IMRT (40% versus 89% diffi-
culty swallowing and 10% versus 44% impaired nutrition in the
reduced-dose versus regular-dose IMRT arms, respectively) [69].
Although the data concerning the utility of ICT in patients with
HPV-associated LA SCCHN are still incomplete, these early
investigations suggest a role for ICT in treatment deintensifica-
tion in patients with favorable prognoses [68].
Selecting a post-TPF regimen
No consensus exists yet regarding the optimal post-TPF regi-
mens, although evidence suggests that some options confer high
toxicity without additional benefit. Radiotherapy alone has the
largest body of evidence in cases where organ preservation is the
primary objective [9, 10], yet other regimens (radiotherapy plus
either carboplatin, PF or cetuximab) have shown encouraging
results in the post-ICT setting in smaller studies [12, 69].
However, phase III randomized trials are imperative to further
establish these regimens’ role in sequential chemotherapy
treatment.
Cisplatin’s inclusion in both TPF (75 mg/m2 q3w) and the
follow-up chemoradiotherapy (100 mg/m2 q3w) regimen have
been generally associated with low adherence and unacceptably
high rates of toxicity [33, 70]. A study of 65 patients randomized to
receive either high-dose (100 mg/m2 q3w) or weekly (40 mg/m2)
cisplatin plus radiotherapy following 4 cycles of TPF was termi-
nated early because only 32% of all patients were able to receive the
full planned cisplatin dose due to toxicity [70]. Although patients
receiving weekly cisplatin were twice as likely to receive the full
planned dose (22% versus 41% in the high-dose versus weekly cis-
platin arms, respectively), no difference in OS rate was observed at
2 years between the two arms [70]. Although the vast majority of
patients included in this study were still able to receive> 90% of
the planned dose of radiotherapy [70], this study suggested that it
is inadvisable to administer high cumulative cisplatin doses
(300 mg/m2) post-TPF due to associated toxicity issues and low
adherence to the systemic component of the treatment.
Furthermore, the same study suggested also that the weekly cis-
platin schedule failed to provide a milder alternative to high-dose
cisplatin. Notably, while chemoradiotherapy (with cisplatin
100 mg/m2 q3w) plus cetuximab resulted in significantly higher
toxicity (with no improvement in efficacy) than chemoradiother-
apy alone, even without prior induction treatment [71], certain
subgroups of patients may benefit from this regimen. In a retro-
spective analysis of the RTOG 0522 study, the presence of genetic
variants appeared to correlate with improved survival with the
addition of cetuximab to cisplatin and radiotherapy [72]. The
randomized, phase II TREMPLIN study in previously untreated
patients with stages III to IV laryngeal/hypopharyngeal SCC
administered three cycles of the TAX 323/EORTC 24971 TPF regi-
men [12]. Poor responders (<50% tumor shrinkage) underwent
salvage surgery. Responders (50% tumor shrinkage) were
randomly assigned to conventional radiotherapy (70 Gy) with
concurrent cisplatin (100 mg/m2/day) on days 1, 22, and 43
of radiotherapy or concurrent cetuximab (400-mg/m2 loading
dose and 250 mg/m2/week) during radiotherapy. Many patients
ended participation in the trial before receiving the radiotherapy-
based portion of the treatment. However, those who did and
were randomized to the cetuximab and radiotherapy arm had
fewer treatment interruptions and a higher rate of treatment com-
pletion than those randomized to the cisplatin and radiotherapy
arm [12, 35]. Despite that, more relapses occurred in the cetuxi-
mab/radiotherapy arm than in the cisplatin/radiotherapy arm (the
majority of which could be salvaged by surgery) with no difference
in OS [12, 35]. This finding needs to be confirmed in a phase III
setting with an amended trial design which hopefully will allow a
final conclusion on this topic. Finally, carboplatin or PF can also
be paired with radiotherapy as post-ICT regimens, as used in TAX
324 and in the Italian trial, respectively. Both combination treat-
ments demonstrated favorable safety results, and the majority of
patients completed those regimens [3, 5, 27]. However, no results
are available directly comparing the combination of radiotherapy
with cisplatin versus radiotherapy plus carboplatin or PF. From
the meta-analyses performed until now, comparing carboplatin/
radiotherapy and cetuximab/radiotherapy to cisplatin/radiother-
apy in the LA SCCHN setting [73–75], it can be concluded that the
standard cisplatin-based chemoradiation should remain the stand-
ard of care until equivalence with carboplatin or cetuximab has
been prospectively demonstrated. Moreover, none of these regi-
mens have been fully investigated in the post-ICT setting.
Therefore, as carboplatin and cetuximab both may offer more tol-
erable alternatives to cisplatin in chemoradiation after cisplatin-
based ICT, their further investigation in that setting is warranted.
Also of note, as immune checkpoint inhibitors gain approval and
are increasingly tested in combinations with other therapies, their
potential role in follow-up therapy will require examination.
Immunotherapies’ toxicity profiles are encouraging and may be-
come a key factor in determining their place within the treatment
paradigm.
Discussion
Conclusion
By examining the available data from phase III, randomized clin-
ical trials investigating TPF regimens, we have concluded that
TPF is the current evidence-based gold standard for ICT. The fa-
vorable efficacy and safety profiles with TPF over PF have been
clearly demonstrated, particularly in the TAX 323/EORTC 24971
and TAX 324 studies. Currently, the only guideline-mandated in-
dication for TPF is as an induction regimen before radiotherapy
in patients requiring total laryngectomy, with organ preservation
as the main objective [11]. We maintain, however, that while the
exact patient populations who stand to gain the most benefit
from induction remain to be fully defined, TPF has an important
role in various situations. In operable disease, TPF ICT can re-
duce the rates of local and DF and enhance organ preservation
and function. In patients with unresectable disease, TPF ICT
improves survival over PF. While no definitive conclusions can
be made about whether TPF ICT is an overall superior treatment
to concurrent chemoradiotherapy, certain patient subgroups
(those with high-risk disease or for whom organ preservation and
reducing the probability of distant relapse are key end goals)
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could gain important benefits with sequential over concurrent
therapy. Additionally, TPF ICT could provide a new avenue of
radiotherapy de-intensification in patients with favorable prog-
noses. Although ICT! radiotherapy alone has the largest avail-
able body of evidence, other options warrant further
investigation. Cisplatin/radiotherapy appears to come with ser-
ious toxicity and adherence concerns for most patients, especially
after ICT with high cumulative cisplatin dosages. Although
cetuximab and carboplatin with radiotherapy could represent
safer options, more data need to be collected for these regimens.
Further investigation in phase III trials is warranted. Future
investigations must determine the optimal post-ICT TPF regi-
mens and further characterize those patients who stand to gain
significant benefits in terms of survival and organ function with
sequential over concurrent chemoradiotherapy regimens.
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